Direct Minimally Invasive Intramyocardial Injection of Bone Marrow-Derived AC133+ Stem Cells in Patients with Refractory Ischemia: Preliminary Results

Abstract

Background: Bone marrow-derived stem cells (BMSC) may represent a viable option for patients with myocardial ischemia refractory to conventional treatments. Material and Methods: In 5 patients (4 males and 1 female, mean age 64 ± 8 years) with untreatable angina pectoris (Canadian Cardiovascular Society Class III/IV), myocardial segments with stress-induced ischemia as assessed by gated single-photon emission computed tomography were injected with 4 to 12 million CD133+ BMSC. Cells were injected into the myocardium (2 anterior, 2 lateral, 1 inferior wall) through minimally invasive approaches (left minithoracotomy [n = 4] and subdiaphragmatic approach [n = 1]). At baseline, at 6 months and at 1 year of follow-up, an exercise test, gated single-photon emission computed tomography (SPECT), 2-D echocardiography and coronary angiography were performed to assess exercise capacity, myocardial perfusion, LV function and coronary anatomy. Results: Intramyocardial injection of autologous CD133+ BMSC cells was safe. No early or long-term complications were observed. After an average of 3.8 weeks from cell inoculation, all patients experienced a significant improvement of CCS class (from 3.8 to 1.8 at 6 months) and serial SPECT documented improvements of rest and stress perfusion in the injected territories at 6 months from operation. In 3 cases, coronary angiography showed an increase in the collateral score of the target areas. Clinical improvements still persist unchanged in 4 out of 5 cases at a mean of 36.5 months postoperatively. Conclusions: After stand-alone BMSC transplantation for refractory myocardial ischemia, we observed long-term clinical and perfusion improvements in the absence of adverse events.

coronary artery disease - refractory ischemia - stem cells

References

• 1 Fuchs S, Satler L F, Kornowski R. et al . Catheter-based autologous bone marrow myocardial injection in no option patients with advanced coronary artery disease.  J Am Coll Cardiol. 2003;  41 1721-1724
• 2 Tse H F, Kwong Y L, Chan J KF, Lo G, Ho C L, Lau C P. Angiogenesis in ischemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation.  Lancet. 2003;  361 47-49
• 3 Beeres S LMA, Bax J J, Kaandorp T AM. et al . Usefulness of intramyocardial injection of autologous bone marrow-derived mononuclear cells in patients with severe angina pectoris and stress-induced myocardial ischemia.  Am J Cardiol. 2006;  97 1326-1331
• 4 Perin E C, Dohmann H FR, Borojevic R. et al . Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy.  Circulation. 2004;  110 (Suppl II) II‐213-II‐218
• 5 Asahara T, Masuda H, Takahashi T. et al . Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.  Circ Res. 1999;  85 221-228
• 6 Fuchs S, Baffour R, Zhou Y F. et al . Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia.  J Am Coll Cardiol. 2001;  37 1726-1732
• 7 Kinnaird T, Stabile E, Burnett M S, Epstein S E. Bone-marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences.  Circ Res. 2004;  95 354-363
• 8 Pompilio G, Capogrossi M C, Cannata A. et al . Endothelial progenitor cells: a potential versatile tool for the treatment of ischemic cardiomyopathies - a clinician's point of view.  Int J Cardiol. 2004;  95 (Suppl 1) S34-S37
• 9 Takahashi T, Kalka C, Masuda H. et al . Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization.  Nat Med. 1999;  5 434-438
• 10 Asahara T, Masuda H, Takahashi T. et al . Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.  Circ Res. 1999;  85 221-228
• 11 Kinnaird T, Stabile E, Burnett M S. et al . Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms.  Circulation. 2004;  109 1543-1549
• 12 Reyes M, Dudek A, Jahagirdar B. et al . Origin of endothelial progenitors in human postnatal bone marrow.  J Clin Invest. 2002;  109 337-346
• 13 Pompilio G, Cannata A, Peccatori F. et al . Autologous peripheral blood stem cells transplantation for myocardial regeneration: a novel strategy for cell collection and surgical injection.  Ann Thorac Surg. 2004;  78 1808-1813
• 14 Pompilio G, Cannata A, Pesce M, Capogrossi M C, Biglioli P. Long-lasting improvement of myocardial perfusion and chronic refractory angina after autologous intramyocardial PBSC transplantation.  Cytotherapy. 2005;  7 494-496
• 15 Stamm C, Westphal B, Kleine H D. et al . Autologous bone marrow stem-cell transplantation for myocardial regeneration.  Lancet. 2003;  361 45-46
• 16 Cerqueira M D, Weissman N J, Dilsizian V. et al . Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.  Circulation. 2002;  105 539-542
• 17 van't Hof A WJ, Liem A, Suryapranta H. Angiographic assessment of myocardial reperfusion in patients treated with primary coronary angioplasty for acute myocardial infarction. Myocardial blush grade.  Circulation. 1998;  97 2302-2306
• 18 Berman D S, Abidov A, Kang X. et al . Prognostic validation of a 17-segment score derived from a 20-segment score for myocardial perfusion SPECT interpretation.  J Nucl Cardiol. 2004;  11 414-423
• 19 Klein H M, Ghodsizad A, Marktanner R. et al . Intramyocardial implantation of CD133+ stem cells improved cardiac function without bypass surgery.  Heart Surg Forum. 2007;  10 E66-E69
• 20 Archundia A, Aceves J L, Lopez-Hernandez M. et al . Direct cardiac injection of G‐CSF mobilized bone-marrow stem-cells improves ventricular function in old myocardial infarction.  Life Sci. 2005;  78 279-283
• 21 Briguori C, Reimers B, Sarais C. et al . Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina.  Am Heart J. 2006;  151 674-680
• 22 Beeres S L, Bax J J, Dibbets P. et al . Effect of intramyocardial injection of autologous bone marrow-derived mononuclear cells on perfusion, function, and viability in patients with drug-refractory chronic ischemia.  J Nucl Med. 2006;  47 574-580
• 23 Perin E C, Dohmann H FR, Borojevic R. et al . Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure.  Circulation. 2003;  107 2294-2302
• 24 Losordo D W, Shatz R A, White C J. et al . Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/II, double-blind randomized controlled trial.  Circulation. 2007;  115 3165-3172
• 25 Dongming Hou. Eyas Al-Shaykh Youssef . Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery implications for current clinical trials.  Circulation. 2005;  112 (Suppl 1) I‐150-I‐156
• 26 DeJongste M JL, Tio R A, Foreman R D. Chronic therapeutically refractory angina pectoris.  Heart. 2004;  90 225-230
• 27 Kornowski R, Fuchs S, Zafrir N. Refractory myocardial ischemic syndromes: patients' characterization and treatment goals.  Future Cardiol. 2005;  1 629-635
• 28 Goldberg R F, Fass A E, Frishman W H. Transmyocardial revascularization: defining its role.  Cardiol Rev. 2005;  13 52-55
• 29 Werner N, Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells. Limitation for therapy?.  Arterioscl Thromb Vasc Biol. 2006;  26 257-266
• 30 Iwaguro H, Yamaguchi J, Kalka C. et al . Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration.  Circulation. 2002;  105 732-738